B.Riley Financial analyst Mayank Mamtani maintained a Hold rating on Madrigal Pharmaceuticals (MDGL – Research Report) today and set a price target of $75.00. The company’s shares opened today at $74.13.
Mamtani covers the Healthcare sector, focusing on stocks such as Altimmune, Novavax, and Intercept Pharma. According to TipRanks, Mamtani has an average return of -29.6% and a 22.16% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Madrigal Pharmaceuticals with a $149.50 average price target.
MDGL market cap is currently $1.26B and has a P/E ratio of -4.90.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.
Read More on MDGL:
- JMP Securities biotech analyst to hold an analyst/industry conference call
- Piper says Akero data increases conviction in Madrigal NASH readout
- Oppenheimer Says Biotech Stocks Look a Bit Brighter Right Now; Here Are 2 Names to Consider
- Madrigal Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference